Company: LIMN
Filing Date: 2025-01-27
Form Type: POS AM
Source: 0001104659-25-006325
Chunk: 732

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-27
Form: POS AM
Chunk 732
---
 under this Subscription Agreement;

(iv)

there shall have been no amendment, waiver, or modification to any Other Subscription Agreements that materially benefits any Other Subscribers unless Subscriber has been offered substantially similar benefits in writing;

(v)

the Issuer’s listing application with NYSE, NYSE American or Nasdaq in connection with the closing of the Transaction shall have been conditionally approved and, immediately following the closing of the Transaction pursuant to the Transaction Agreement, the Issuer shall satisfy any applicable initial listing requirements of one of NYSE, NYSE American or Nasdaq and the Issuer shall not have received any notice of noncompliance therewith;

(vi)

The Issuer shall have executed and delivered the Registration Rights Agreement; and

(vii)

Subscriber shall have received a certificate signed by an officer of the Issuer, dated the Closing Date, in which such officer shall state that the conditions set forth in Section 2(e)(i) and Section 2(e)(ii) are satisfied as of the Closing Date.

<div align='center'>E-3</div>

TABLE OF CONTENTS

(f) Prior to or at the Closing, Subscriber shall deliver all such other information and shall take all such actions as are reasonably requested by the Issuer or IRIS in order for the Issuer to issue the Subscribed Shares to Subscriber.

Section 3. Issuer Representations and Warranties . The Issuer and IRIS severally, and not jointly, represent and warrant to Subscriber that:

(a) Each of the Issuer and IRIS (i) is duly organized, validly existing and at the time of the Closing in good standing under the laws of its jurisdiction of incorporation, (ii) has the requisite power and authority to own, lease and operate its properties, to carry on its business as it is now being conducted and to enter into, deliver and perform its obligations under this Subscription Agreement, and (iii) is duly licensed or qualified to conduct its business and, if applicable, is in good standing under the laws of each jurisdiction (other than their jurisdiction of incorporation) in which the conduct of its business or the ownership of its properties or assets requires such license or qualification, except, with respect to the foregoing clause (iii) , where the failure to be in good standing would not reasonably be expected to have an Issuer or IRIS Material Adverse Effect. For purposes of this Subscription Agreement, an “ Issuer or IRIS Material Adverse Effect ” means an event, change, development, occurrence, condition or effect which